<![CDATA[AOP Orphan Pharmaceuticals GmbH 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=40861>Thu, 30 Apr 2026 02:53:01 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health]]>https://www.newswire.co.kr/newsRead.php?no=1033236Mon, 27 Apr 2026 15:20:00 +0900<![CDATA[프랑크푸르트 고등법원, AOP 헬스에 유리한 BESREMi® 중재 판정 유지]]>https://www.newswire.co.kr/newsRead.php?no=1033240Mon, 27 Apr 2026 15:20:00 +0900<![CDATA[U.S. FDA Approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting]]>https://www.newswire.co.kr/newsRead.php?no=1001767Thu, 28 Nov 2024 10:15:00 +0900<![CDATA[미국 FDA, 중환자의 심방세동 및 심방초동을 위한 AOP 헬스의 래피블릭 승인]]>https://www.newswire.co.kr/newsRead.php?no=1001768Thu, 28 Nov 2024 10:15:00 +0900<![CDATA[Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells]]>https://www.newswire.co.kr/newsRead.php?no=997868Wed, 02 Oct 2024 13:45:00 +0900<![CDATA[AOP 헬스, 암 줄기세포를 표적으로 하는 새로운 암치료 접근법 연구]]>https://www.newswire.co.kr/newsRead.php?no=997870Wed, 02 Oct 2024 13:45:00 +0900<![CDATA[Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results]]>https://www.newswire.co.kr/newsRead.php?no=991400Wed, 12 Jun 2024 10:25:00 +0900<![CDATA[혈액학/종양학: AOP 헬스의 임상 연구 프로그램 확장으로 새로운 결과 제공]]>https://www.newswire.co.kr/newsRead.php?no=991402Wed, 12 Jun 2024 10:25:00 +0900<![CDATA[AOP Health Receives Market Authorization for Landiolol in Canada]]>https://www.newswire.co.kr/newsRead.php?no=981011Thu, 14 Dec 2023 12:10:00 +0900<![CDATA[AOP 헬스, 캐나다에서 란디올롤 시판 승인 획득]]>https://www.newswire.co.kr/newsRead.php?no=981012Thu, 14 Dec 2023 12:10:00 +0900<![CDATA[Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia]]>https://www.newswire.co.kr/newsRead.php?no=974849Wed, 20 Sep 2023 15:05:00 +0900<![CDATA[혈액암: AOP 헬스, 의학 저널 루키미어에 진성다혈구증 환자 대상 새 연구 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=974850Wed, 20 Sep 2023 15:05:00 +0900<![CDATA[AOP 헬스, 백혈병 치료 위한 연구 시작]]>https://www.newswire.co.kr/newsRead.php?no=948890Mon, 01 Aug 2022 17:45:46 +0900<![CDATA[AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting]]>https://www.newswire.co.kr/newsRead.php?no=946592Tue, 21 Jun 2022 15:45:00 +0900<![CDATA[AOP 헬스, EHA 2022 연례 회의서 ‘CONTINUATION-PV’ 연구 결과 발표… 베스레미(로페그인터페론알파-2b) 이용한 7년 6개월의 진성적혈구증가증 환자 치료 여정 마무리]]>https://www.newswire.co.kr/newsRead.php?no=946593Tue, 21 Jun 2022 15:45:00 +0900